The excess mortality risk associated with high or very low glycated hemoglobin values is modified by glycemic variability in diabetes patients aged 70 years or more, shows an analysis of The Health Improvement Network database.
Experts review the evidence and best clinical practices of initiating and titrating insulin in patients with type 2 diabetes and provide guidance and practical recommendations for the healthcare community.
As the utility and availability of devices surges, so too do patient expectations. Prof. Katharine Barnard provides key consultation questions to help determine your patients’ greatest needs and obstacles.
The excess mortality risk associated with high or very low glycated hemoglobin values is modified by glycemic variability in diabetes patients aged 70 years or more, shows an analysis of The Health Improvement Network database.
Analysis of the research to date comparing artificial pancreas treatment with other insulin systems supports its ability to significantly improve glycemic control in patients with type 1 diabetes, while reducing the burden of hypoglycemia.
Secondary analysis of the PARADIGM-HF trial shows that the adverse effects of diabetes on kidney function can be ameliorated by a neprilysin inhibitor.
Analysis of the DIAMOND study shows that continuous glucose monitoring in patients with type 1 diabetes could be considered cost-effective, although this depends on the value for money threshold used.
A network meta-analysis published in JAMA offers indirect comparisons of the survival benefits associated with use of the most recent antidiabetic agents.
